LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Phreesia Inc

Gesloten

SectorGezondheidszorg

31.99 3.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.85

Max

32.08

Belangrijke statistieken

By Trading Economics

Inkomsten

2.5M

-3.9M

Verkoop

6.3M

116M

Winstmarge

-3.376

Werknemers

2,082

EBITDA

2M

4.1M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+6.75% upside

Dividenden

By Dow Jones

Volgende Winsten

4 sep 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

378M

1.8B

Vorige openingsprijs

28.09

Vorige sluitingsprijs

31.99

Nieuwssentiment

By Acuity

12%

88%

6 / 372 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Phreesia Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 aug 2025, 22:51 UTC

Winsten

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Rev $4.01B

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Adj EPS $1.84

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H EPS $1.82

27 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug 2025, 23:39 UTC

Winsten

Correction to Nvidia Earnings Article -- WSJ

27 aug 2025, 22:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 aug 2025, 22:59 UTC

Marktinformatie

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug 2025, 22:58 UTC

Winsten

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug 2025, 22:57 UTC

Winsten

South32 FY Free Cash Flow $192 Million

27 aug 2025, 22:56 UTC

Winsten

South32 FY Total Capital Expenditure $1.35 Billion

27 aug 2025, 22:56 UTC

Winsten

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug 2025, 22:55 UTC

Winsten

South32 Net Cash $123 Million at June 30

27 aug 2025, 22:54 UTC

Winsten

South32: Focused on Maintaining Strong Operating Momentum

27 aug 2025, 22:53 UTC

Winsten

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug 2025, 22:53 UTC

Winsten

South32 Extends Capital Management Program for 12 Months

27 aug 2025, 22:52 UTC

Winsten

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug 2025, 22:50 UTC

Winsten

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug 2025, 22:50 UTC

Winsten

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug 2025, 22:45 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug 2025, 22:43 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug 2025, 22:43 UTC

Winsten

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources Net Debt $123 Million at June 30

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Vergelijking

Prijswijziging

Phreesia Inc Prognose

Koersdoel

By TipRanks

6.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 32.88 USD  6.75%

Hoogste 36 USD

Laagste 29 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Phreesia Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Technische score

By Trading Central

25.23 / 25.61Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

6 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Phreesia Inc

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.